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Simple Summary: Penile squamous cell carcinoma (PSCC) is the most common type of penile cancer
(PeCa) and is associated with human papillomavirus (HPV) in about 50% of cases. It is of high clinical
impact to identify patients who are at high risk of metastasis and are likely to benefit from adjuvant
therapies. Today, valid prognostic biomarkers are scarce in penile cancer. In the present study, we
attempted to identify miRNAs involved in tumor development and metastasis in distinct histological
subtypes with or without HPV infection in PSCC patients. We confirmed that specific miRNAs could
serve as potential diagnostic and prognostic markers in single PSCC subtypes and are associated
with HPV infection.
Abstract: Although microRNAs are described as promising biomarkers in many tumor types, little
is known about their role in PSCC. Thus, we attempted to identify miRNAs involved in tumor
development and metastasis in distinct histological subtypes considering the impact of HPV infection.
In a first step, microarray analyses were performed on RNA from formalin-fixed, paraffin-embedded
tumor (22), and normal (8) tissue samples. Microarray data were validated for selected miRNAs by
qRT-PCR on an enlarged cohort, including 27 tumor and 18 normal tissues. We found 876 significantly
differentially expressed miRNAs (p ≤ 0.01) between HPV-positive and HPV-negative tumor samples
by microarray analysis. Although no significant differences were detected between normal and tumor
tissue in the whole cohort, specific expression patterns occurred in distinct histological subtypes,
such as HPV-negative usual PSCC (95 differentially expressed miRNAs, p ≤ 0.05) and HPV-positive
basaloid/warty subtypes (247 differentially expressed miRNAs, p ≤ 0.05). Selected miRNAs were
confirmed by qRT-PCR. Furthermore, microarray data revealed 118 miRNAs (p ≤ 0.01) that were
significantly differentially expressed in metastatic versus non-metastatic usual PSCC. The lower
expression levels for miR-137 and miR-328-3p in metastatic usual PSCC were validated by qRT-PCR.
The results of this study confirmed that specific miRNAs could serve as potential diagnostic and
prognostic markers in single PSCC subtypes and are associated with HPV-dependent pathways.
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1. Introduction
The incidence of penile cancer (PeCa) is low at 0.3 to 1.0 per 100,000 in Western Europe
and the United States. The most common PeCa type is penile squamous cell carcinoma
(PSCC) [1–3]. A recent systematic review and meta-analysis of the published literature
found that human papillomavirus (HPV) DNA is detectable in 50.8% of penile cancer
cases, of which HPV-16 is the most prevalent viral subtype, accounting for 63% of the HPV-
attributable cases, followed by HPV-6 (8.1%), HPV-18 (6.9%), and, to a lesser extent, HPV-11,
HPV-45, HPV-33, HPV-52, and HPV-31, among others [4]. As such, the 2016 WHO classifi-
cation categorizes PSCC into HPV-related (such as basaloid, warty, and warty–basaloid)
and non-HPV-related subtypes, which include the usual histological subtype as the most
common [5,6]. Previous studies have explained two different mechanisms for oncogenesis
in PSCC. First, the HPV-independent mechanism is linked to p53 mutation and shows
nuclear p53 expression in atypical basal keratinocytes without P16INK4a expression [7–9].
P16INK4a downregulation through overexpression of the BMI-1 polycomb gene and inacti-
vation of P16INK4a through DNA methylation has also been described in PSCC [10,11].
Second, the HPV-dependent mechanism involves E6 and E7 viral oncoproteins binding
to p53 and retinoblastoma gene protein Rb. These host regulatory proteins disrupt DNA
repair, growth arrest, apoptosis via E6 [12], and inactivation of hypo-phosphorylated Rb
protein via E7, resulting in nuclear accumulation of cyclin-dependent kinase inhibitor
P16INK4a [10,13–15].
In contrast to the well-known role of HPV in tumor development, the impact of HPV
infection on the prognosis of PSCC remains unclear and is still under discussion [16–18].
It is of high clinical impact to identify patients who are at a high risk of metastasis and
are likely to benefit from invasive therapies such as early inguinal lymph node dissection or
adjuvant systemic chemotherapy. We and others proved regional lymph node involvement
and lymph vessel invasion as independent prognostic factors in PSCC [19–21]. However,
these parameters are not sufficient for individual therapy selection to improve treatment in
high-risk patients and to prevent adverse effects in low-risk patients. Therefore, prognostic
biomarkers are urgently needed.
miRNAs are conserved, short, single-stranded, non-coding RNAs of 19 to 25 nu-
cleotides involved in post-transcriptional regulation of target genes by binding to the
3′ untranslated regions (3′UTRs) of the messenger RNA (mRNA) [22,23]. It has been
shown that miRNAs play a crucial role in a broad range of biological processes, such as
the proliferation, metabolism, apoptosis, and metastasis of tumors [24–26]. Changes in
miRNA expression have been reported in a variety of human tumors and can potentially
be employed as clinical biomarkers of diagnosis, prognosis, metastasis, and therapy resis-
tance [27,28]. It was previously revealed that HPV infection via viral oncoproteins E6 and
E7 altered the expression of cellular oncogenic and tumor suppressor miRNAs by modulat-
ing the c-Myc, p53, and E2F genes [29–31]. While it can be concluded that HPV infection
has an effective impact on many biological processes, particularly through its interaction
with the miRNA network, the impact of HPV infection on miRNA expression in PSCC
remains unclear [16–18]. Furthermore, little is known about the role of miRNAs in tumor
development and progression in this tumor type in general, and even less in histological
subtypes. Therefore, miRNA expression analyses were performed in the present study
to identify deregulated miRNAs associated with tumorigenesis and metastasis in distinct
histological subtypes of PSCC considering HPV status.
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2. Materials and Methods
2.1. Sample Collection and Patient Data
The patient samples were obtained from urology departments in Germany and Russia
as described in our previous cohort study [19] (Table 1 and Table S1). Thirty samples,
including 22 tumor tissue and 8 normal tissue samples, were used for screening by microar-
ray analysis. For validation by PCR, 45 samples (27 tumor and 18 normal tissue samples)
were analyzed, including those from the screening cohort. The hematoxylin and eosin
(H&E)-stained tissue sections were assessed by two pathologists to confirm histologic sub-
types as previously described [19]. Written informed consent was obtained from patients
in most cases. For those individuals from whom we could not obtain informed consent, the
data were analyzed anonymously. A regional ethics committee approved this investigation
(Saarland ethical committee votes: 42/17, 220/19).
Table 1. Summary of the clinical and histopathological data of the penile squamous cell carcinoma
(PSCC) samples. n/a: Not available. In addition to lymph node metastases, visceral metastases were
found in liver and lung. HPV: Human papillomavirus.
PATIENT CHARACTERISTICS N %




clear cell 1 2.9
verrucous 1 2.9














METASTASIS STATUS Non-metastatic 18 51.4
Metastatic 17 48.6
HPV STATUS HPV+ 17 48.6
HPV- 18 51.4
2.2. DNA and RNA Isolation
Total DNA and RNA (including small RNA) were isolated from formalin-fixed,
paraffin-embedded (FFPE) tissue sections, prepared by punches from defined tumor-
affected or normal areas, using AllPrep® DNA/RNA FFPE Kits (Qiagen, Hilden Germany)
according to the manufacturer’s instructions. Detection of HPV infection was performed
by HPV polymerase chain reaction (PCR) for GP5+/6+ and Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) primers using the LightCycler® 1.5 instrument (Roche Diagnos-
tics GmbH) as previously described [19,32]. The concentration and purity of the RNA was
assessed using the ratio of absorbance levels at 230, 260, and 280 nm, determined using a
NanoDrop™ ND-1000 Spectrophotometer (ThermoFisher Scientific, Dreieich, Germany).
2.3. miRNA Microarray and Data Analysis
MicroRNA labelling and hybridization were performed using the miRNA Complete
Labelling and Hybridization Kit (Agilent, Waldbronn, Germany) according to the manu-
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facturer’s instructions. Briefly, 100 ng of isolated RNA from PSCC and normal tissue was
dephosphorylated, labelled with pCp-Cy3, and hybridized to the Agilent human miRNA
microarray. Microarray data analysis was performed using Qlucore Omics Explorer 3.5
(Qlucore AB, Lund, Sweden). In brief, microarrays were scanned using the Agilent Microar-
ray Scanner, and expression values were extracted using the Agilent Feature Extraction (FE)
software. Unpaired Student t-tests were performed using Qlucore Omics Explorer. The
differential expression of miRNA between groups was considered statistically significant
when p-values were less than 0.05, false discovery rates (q) were less than 0.3, and a 2-fold
change in miRNA expression was detected. The total gene signal was normalized to the
75th percentile of signal intensity. Unsupervised hierarchical clustering and principal
component analysis (PCA) were also conducted using Qlucore Omics Explorer.
2.4. Real-Time RT-PCR Quantification of miRNAs
To validate the miRNA microarray data, reverse transcription PCR (qRT-PCR) was
performed using TaqMan® MicroRNA Reverse Transcription Kits or TaqMan® Advanced
miRNA cDNA Synthesis Kits, followed by a polymerase chain reaction (PCR) step using
specific TaqMan® miRNA primers and TaqMan® Fast Advanced Master Mix, according to
the manufacturer’s protocol. PCRs were run in triplicate using LightCycler® 480 (Roche
diagnostics Deutschland GmbH, Mannheim, Germany). miR-191-5p (ThermoFisher) was
used as an endogenous control to normalize miRNA input in the real-time PCR (qRT-PCR)
assay. The relative quantitative method of 2−∆∆CT was used to measure changes in selected
miRNAs. The ∆Ct value was calculated by subtracting the Ct values of miR-191-5p from
the Ct values of the miRNA of interest. Deregulation of miRNA was considered validated
if there was at least a 2-fold expression difference between each group and the deregulation
was in the same direction as in the microarray data. Ct values above 35 were considered
as not expressing miRNA. The nonparametric Mann–Whitney U test was used to analyze
the qRT-PCR data (IBM® SPSS® Statistics version 25). A p-value of less than 0.05 was
considered a statistically significant threshold for upregulated or downregulated miRNA.
3. Results
3.1. Microarray Analysis
To determine the possible association between HPV infection and miRNA expression
and to test whether miRNAs could serve as diagnostic or prognostic markers, 12 HPV-
negative and 10 HPV-positive tumor samples of different histological subtypes, as well
as 8 non-tumor tissue samples related to both HPV-positive and HPV-negative tumors,
were subjected to miRNA microarray analysis. The comparison of HPV-positive and HPV-
negative cases revealed significant differences in miRNA expression profiles (Figure 1a). In
total, 876 miRNAs showed significantly different expression between HPV-positive and
HPV-negative tumors (p ≤ 0.01, q ≤ 0.027), including 868 downregulated and 8 upregu-
lated miRNAs in HPV-positive PSCC (Table S2). However, we could not find statistically
significant differences in miRNA expression profiles between HPV-related and non-HPV-
related histological subtypes (Figure S1) (q ≥ 0.81). There was also a statistically significant
difference between non-tumor tissues based on HPV status (p ≤ 0.05, q ≤ 0.37), resulting
in the upregulation of 24 miRNAs and the downregulation of 12 miRNAs in HPV-positive
cases (Figure 1b). Surprisingly, we did not find significant differences in miRNA expression
between tumor and normal samples in general (q ≥ 0.99) (Figure S2). From PCA and
hierarchical clustering of the miRNA expression profiles of usual, warty, basaloid, and
warty–basaloid PSCC subtypes, we found distinct miRNA profiles of basaloid tumors,
and we found the usual subtype to be closer to the warty and warty–basaloid subtypes
(F ≤ 0.01; Figure 2).
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Figure 1. Heat map after unsupervised hierarchical clustering of differentially expressed miRNAs in HPV-positive versus 
HPV-negative (a) PSCC tumor tissues (p ≤ 0.01; q ≤ 0.027; fold change ≥ 2) and (b) normal tissues (p ≤ 0.05; q ≤ 0.37; fold 
change ≥ 2). 
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Figure 1. Heat map after unsupervised hierarchical clustering of differentially expressed miRNAs in HPV-positive versus
HPV-negative (a) PSCC tumor tissues (p ≤ 0.01; q ≤ 0.027; fold change ≥ 2) and (b) normal tissues (p ≤ 0.05; q ≤ 0.37; fold
change ≥ 2).





Figure 1. Heat map after unsupervised hierarchical clustering of differentially expressed miRNAs in HPV-positive versus 
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Figure 2. Multiple group comparison of differentially expressed miRNAs in basaloid, warty–basaloid, warty, and usual
histological subtypes using the F-test (q ≤ 0.01). (a) Heatmap; (b) principal component analysis plot.
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Based on these differences, we further investigated miRNA expression in the context
of histological subtypes considering HPV status. A comparison of the profiles of the HPV-
negative usual subtype and normal tissues revealed 95 differentially expressed miRNAs,
including 91 that were upregulated and 4 that were downregulated in tumor tissue with
a 2-fold change (p ≤ 0.05, q ≤ 0.23; Figure 3 and Table S3). In this comparison, miR-
4512 had the highest expression, with a 5.1-fold increase, and miR-99a-5p had the lowest
expression, with an 8-fold decrease, relative to normal tissue. To identify deregulated
miRNAs involved in metastasis within this subgroup, the miRNA expression profiles
in metastatic versus non-metastatic tissues were then analyzed (Figure 4 and Table S4).
They were found to be statistically significantly different (p ≤ 0.01, q ≤ 0.08), with a total
of 118 significantly deregulated miRNAs, of which 28 were upregulated and 90 were
downregulated in metastatic tumors. Here, miR-4498 had the highest expression, with a
5.4-fold increase, whereas miR-137 (with a 3.7-fold decrease) and miR-301b (with a 4-fold
decrease) had the lowest expression in usual metastatic tumors.
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Due to the low frequency of basaloid tumors and the histological similarities between
warty, basaloid, and warty–basaloid tumors, these three PSCC subtypes were combined
into a single group. A comparison of this HPV-positive group to the related normal tissues
revealed 247 miRNAs that were differently expressed (p ≤ 0.05, q ≤ 0.17). The majority of
the miRNAs (n = 245) were downregulated, while only two were upregulated (Figure 5).
Here, miR-181d-5p had the highest expression, with a 3.41-fold increase, whereas miR-211-
5p had the lowest expression, with a 16.96-fold decrease in tumor tissue (Table S5). The
analysis of microarray data did not reveal statistically significantly deregulated miRNAs
between metastatic and non-metastatic tissues in these subtypes (q ≥ 0.79; Figure S3).
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137 (p = 0.004) and miR-328-3p (p = 0.032) in metastatic usual subtypes compared to non-
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3.2. Validation of Differentially Expressed miRNAs by qRT-PCR
Based on the results of the microarray analysis (p- and q-values and fold change)
and the potential biological functions in the context of tumorigenesis and metastasis, we
selected eight miRNAs for validation using TaqMan® RT-qPCR from an enlarged cohort,
including samples used for the microarray analyses. We focused on analysis in specific
subtypes as described before. The significantly lower expression level for miR-99a-5p
(p = 0.017) in the HPV-negative usual subtype compared to normal tissue samples was
validated (Figure 6a). No statistically significant differences were found for either miR-
125b-2-3p or miR-105-5p in this subgroup comparison (Figure S4), despite significant
differences in microarray analysis. Furthermore, significantly lower expression levels for
miR-137 (p = 0.004) and miR-328-3p (p = 0.032) in metastatic usual subtypes compared to
non-metastatic tumors were also confirmed (Figure 6b,c). No significant difference was
found for miR-509-5p in this subgroup comparison (Figure S4). Finally, we validated the
higher expression of miR-181d-5p (p = 0.002) (Figure 6d), and no or very low expression of
miR-211-5p was found in the HPV-positive basaloid, warty, and warty–basaloid subtypes
compared to normal tissue (Table 2). Due to the non-significant results of microarray
analysis when comparing the metastatic and non-metastatic tumors, we did not perform
further qRT-PCR experiments.
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Figure 6. Validation of differentially expressed miRNAs in different PSCC histological subtypes as determined by Taq-
Man®  RT-qPCR (p ≤ 0.05). (a) Mean ΔCt values of (HPV-negative) usual PSCC and normal tissue samples; (b,c) mean ΔCt 
values of metastatic versus non-metastatic usual (HPV-negative) tumors; (d) mean ΔCt values of warty–basaloid (HPV-
positive) PSCC versus normal tissue samples. Lower ΔCt implies higher expression level. Mann–Whitney U test was used 
to determine p-values, FC: Fold change. 
4. Discussion 
Currently, no biomarkers are available for the differential diagnosis, prognostic eval-
uation, or therapy response prediction of PSCC. However, this is a clinical need since in-
dividual prognostic evaluation and, therefore, treatment decisions concerning prevention 
of or invasive therapy for metastatic dissemination are still a challenge in this rare but 
often aggressive disease. 
HPV infection is one of the most common risk factors in PSCC [1]. The prognostic 
role of HPV, however, is still debated [19,33–36]. The current WHO classification of PSCC 
is now based on clinicopathologic uniqueness and HPV status, and it assigns histological 
subtypes to HPV-related and non-HPV-related PSCC [5]. It should be considered that 
there is great diversity among histopathological subtypes in the two major groups con-
cerning aggressiveness and outcome. Whereas verrucous and pseudohyperplastic PSCC 
are well differentiated and have an excellent prognosis, pseudoglandular and sarcoma-
toid PSCC are aggressive tumors with poor outcomes, and all are non-HPV-related PSCC. 
Figure 6. Validation of differentially expressed miRNAs in different PSCC histological subtypes as determined by TaqMan®
RT-qPCR (p ≤ 0.05). (a) Mean ∆Ct values of (HPV-negative) usual PSCC and normal tissue samples; (b,c) mean ∆Ct values
of metastatic versus non-metastatic usual (HPV-negative) tumors; (d) mean ∆Ct values of warty–basaloid (HPV-positive)
PSCC versus normal tissue samples. Lower ∆Ct implies higher expression level. Mann–Whitney U test was used to
determine p-values, FC: Fold change.
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4. Discussion
Currently, no biomarkers are available for the differential diagnosis, prognostic eval-
uation, or therapy response prediction of PSCC. However, this is a clinical need since
individual prognostic evaluation and, therefore, treatment decisions concerning prevention
of or invasive therapy for metastatic dissemination are still a challenge in this rare but often
aggressive disease.
HPV infection is one of the most common risk factors in PSCC [1]. The prognostic role
of HPV, however, is still debated [19,33–36]. The current WHO classification of PSCC is
now based on clinicopathologic uniqueness and HPV status, and it assigns histological
subtypes to HPV-related and non-HPV-related PSCC [5]. It should be considered that there
is great diversity among histopathological subtypes in the two major groups concerning
aggressiveness and outcome. Whereas verrucous and pseudohyperplastic PSCC are well
differentiated and have an excellent prognosis, pseudoglandular and sarcomatoid PSCC
are aggressive tumors with poor outcomes, and all are non-HPV-related PSCC. Usual PSCC
represents the most frequent non-HPV-related subtype with heterogeneous outcome. In
HPV-related PSCC, the basaloid subtype represents a poorly differentiated tumor type with
a mainly worse disease course. Therefore, individual histopathological subtypes should be
considered in clinical and molecular studies in addition to the HPV-status.
In the present study, we investigated miRNA expression profiles considering histopatho-
logical subtypes and HPV status. Microarray analysis showed that 876 miRNAs are
differentially expressed at statistically significant levels in HPV-positive relative to HPV-
negative PSCC. This suggests that HPV infection may indeed affect the expression of
miRNAs in PSCC, resulting in distinct molecular pathways, as shown previously [36–38].
Interestingly, a positive HPV status in normal tissue was also associated with changes in
miRNA expression. This could explain why statistically significant differences in miRNA
expression profiles between tumor and normal tissues in general were not identified. In
contrast to the real HPV status, a comparison of HPV-related (subtypes with predominant
but not exclusive HPV infection based on histological subtypes) and non-HPV-related
(subtypes with predominantly negative HPV status with only some HPV infection based
on histological subtypes) PSCC did not reveal statistically significant changes in miRNA
expression as defined by the current WHO classification system [5]. In concordance with
published data, we found that 23% of HPV-negative PSCC are classified as HPV-related
based on histological subtype. These data suggest that real HPV infection, not classification
in HPV-related groups, is the relevant biological event associated with miRNA expression.
As our previous findings support the assertion that histological subtypes are more
relevant than HPV status for prognosis [19], miRNA expression in different histological
subtypes was further analyzed. Since PSCC is a rare tumor, little is known about miRNA
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alterations in distinct histological PSCC subtypes. The results of the present study con-
firm that histological subtypes are characterized by distinct miRNA expression profiles,
especially between basaloid and usual PSCC. Therefore, the miRNA expression in these
two main histological subtypes was further separately investigated. In contrast to the
whole cohort, statistically significant differences in miRNA expression were identified
between normal and tumor tissues in the HPV-negative usual and HPV-positive basaloid,
warty, and warty–basaloid PSCC subtypes. To validate the microarray data, quantification
via qRT-PCR was performed for selected miRNAs. We confirmed the lower expression
of miR-99a-5p in tumor tissues compared to normal tissues in the usual PSCC subtype,
supporting data on the tumor-suppressive role of this miRNA in other tumor types [39–41].
In the miRNA expression profile comparison of the warty, basaloid, and warty–
basaloid group versus normal tissue, miR-211-5p and miR-181d-5p were the most down-
regulated and upregulated miRNAs, respectively. Interestingly, miR-211-5p expression
in this group was not detected at all in tumor tissues based on the cut-off criteria in
qRT-PCR analysis. These results are in line with the microarray data, which found a
16-fold downregulation in miR-211-5p in this group compared to normal samples. These
data are consistent with a previous investigation of small RNA sequencing that found a
300-fold lower expression of miR-211-5p in cancerous penile tissues relative to adjacent
non-cancerous tissues [42]. miR-211-5p has been reported to play a crucial role as a tumor
suppressor in various cancer types [43–46]
The results of the qRT-PCR analysis also confirmed the overexpression of miR-181d-
5p. The upregulation of miR-181d-5p has been found to induce hepatocarcinogenesis [47].
This miRNA packed in exosomes secreted by cancer associated fibroblasts enhances the
epithelial–mesenchymal transition (EMT) and aggressiveness of breast cancer by targeting
caudal-related homeobox 2 (CDX2) [48]. CDX2 loss or reduced expression has been
associated with advanced tumor stage, including metastasis, as well as poor prognosis in
colorectal cancer [49,50]. It is therefore possible that miR-181d-5p overexpression directly
or indirectly reduces the expression of the CDX2 protein in PSCC, enforcing tumorigenesis.
We were then interested in finding putative prognostic miRNAs. We could not detect
miRNA expression differences in association with metastasis in the whole cohort (data
not shown). Therefore, we analyzed altered miRNAs possibly involved in metastasis by
comparing metastatic and non-metastatic HPV-negative usual tumors. We found a clear
pattern that characterized metastatic primary tumors by microarray analysis. The lower
expression of miR-137 and miR-328-3p was confirmed by qRT-PCR. It has been shown that
miR-137, as a tumor suppressor, is downregulated in many cancer types [51–53]. miR-137
overexpression inhibits tumor growth and increases chemosensitivity to paclitaxel and
cisplatin in lung cancer cell lines [54]. In this regard, it would be interesting to investigate
the putative role of this miRNA for chemotherapy response in PSCC, too. Downregulation
of miR-328-3p has been linked to its role as a tumor metastasis suppressor by targeting
matrix metalloproteases [55–57]. Zhang et al. also showed downregulation of miR-328-3p
in penile cancer tissues relative to adjacent non-cancerous tissues by Next-Generation
Small RNA Sequencing [42]. MiRmiR-328-3p inhibits metastasis in colorectal cancer via
inactivation of the PI3K/Akt signaling pathway [58] and reduces invasion as well as EMT
in liver cancer via by targeting endoplasmatic reticulum metallo protease 1 (ERMP1) to
inhibit AKT phosphorylation [59].
We also investigated differential miRNA expression between metastatic and non-
metastatic tumors in combined basaloid, warty, and warty–basaloid subtypes. However,
the heterogeneity in this group was greatly elevated, as reflected by the high false discovery
rate (q ≥ 0.79), perhaps due to the small sample size and heterogeneity. Therefore, the
results were not sufficient for validation using qRT-PCR in this study, and this will be
explored in the future with a larger sample cohort. Our data confirmed that distinct miR-
NAs could serve as prognostic biomarkers in primary tumor tissues to predict metastasis
and could therefore support decision-making for local lymph node treatment, as well as
adjuvant therapy.
Cancers 2021, 13, 1480 11 of 15
It is accepted that the tumor microenvironment plays an important role in tumor
development and progression. In this regard, immune checkpoints are of high interest not
only as prognostic markers, but also as therapeutic targets. High programmed death-ligand
1 (PD-L1) expression is associated with poor prognosis in a variety of solid tumors [60–63].
Forty-eight percent of PSCC cases are PD-L1-positive; these are primarily associated with
HPV-negative subtypes and poor survival [64]. PD-L1 expression is associated with lymph
node metastasis in PSCC patients [64,65]. The correlation between miRNA expression—
including that of miR-138-5p, miR-15a, miR-15b, miR-16, miR-34a, miR-142-5p, and miR-
200—and PD-L1 is well known [60,66–69]. We found by microarray analysis that miR-
138-5p was upregulated in usual PSCC. miR-138-5p is a tumor suppressor that targets
PD-L1 [70–72]. Therefore, it would be interesting to investigate the potential role of miR-
138-5p as a biomarker for therapy selection using checkpoint inhibitors in PSCC patients in
the future.
In general, few data on miRNA expression in PSCC are published. Higher expression
levels of miR-223-3p, miR-107, and miR-21 [36,42,73], and lower expression levels of miR-
1, miR-101, and miR-204, have been reported as potential biomarkers in patients with
PSCC [74]. However, we did not find significant expression differences for the mentioned
miRNAs, which might be due to several reasons, including technical differences. We
used punches from defined tumor and normal areas obtained from FFPE blocks to isolate
RNA. miRNA expression was analyzed by microarrays instead of NGS with different
bioinformatics tools. In addition, possibly more importantly, we investigated the altered
miRNAs in respect to histological subtypes separately. Further studies should also include
long noncoding RNAs as another important class of non-coding RNAs regulating the
complex network of RNA translation.
5. Conclusions
This is the first study, to our knowledge, investigating miRNA expression in PSCC
considering histological subtypes, HPV infection, and metastatic status in a single study.
The identified miRNAs could serve as potential diagnostic and prognostic markers for
single PSCC subtypes. Our data support the assertion that PSCC subtypes are characterized
by distinct molecular alterations and should therefore be investigated separately, as already
shown by clinical data [19]. It seems that HPV infection induces distinct miRNA expression
in PSCC. The influence and degree of altered miRNAs associated with HPV infection in
the different PSCC histological subtypes requires additional research in a larger cohort.
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